Francisco Hernandez-Ilizaliturri, MD, Oncology, Buffalo, NY, Roswell Park Comprehensive Cancer Center

FranciscoHernandez-IlizaliturriMD

Oncology Buffalo, NY

Hematologic Oncology

Chief of the Lymphoma Section, Professor of Medical Oncology, Department of Medicine, Roswell Park Cancer Institute. Associate Professor of Medicine, SUNY Buffalo School of Medicine and Biomedical Sciences

Dr. Hernandez-Ilizaliturri is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hernandez-Ilizaliturri's full profile

Already have an account?

Education & Training

  • University at Buffalo
    University at BuffaloFellowship, Medical Oncology, 1999 - 2002
  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 1996 - 1999
  • Escuela de Medicina Ignacio A. Santos
    Escuela de Medicina Ignacio A. SantosClass of 1995

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2003 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
    Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era
    Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Ce...
    Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)Clinically Relevant Abstract 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Roswell Park Approved to Administer CAR T-cell Therapy, Yescarta, to Lymphoma Patients
    Roswell Park Approved to Administer CAR T-cell Therapy, Yescarta, to Lymphoma PatientsMarch 07, 2018 10:45

Professional Memberships

Other Languages

  • Spanish

Hospital Affiliations